Microbiome-Derived Therapies for Treatment and Prevention of Viral Infections

Lead Inventor:

Ria Goswami, Ph.D.
Assistant Professor of Virology in Pediatrics, Weill Cornell Medical College

Business Development Contact:
Jamie Brisbois
Manager, Business Development and Licensing
(646) 962-7049
jamie.brisbois@cornell.edu
Background & Unmet Need

- There are few antivirals for many viral infections including SARS-CoV-2, influenza, Zika, and CMV
- Limited access to antiretroviral therapy (ART) underlies most new HIV infections and HIV-related deaths
- Barriers to ART and other antivirals include toxicity, side effects, financial constraints, and lack of access to medical care
- There are few broad-spectrum antivirals, which would have the capacity to treat several different viruses
- **Unmet Need**: Development of novel antiviral strategies to overcome the lack of effective treatments, toxicity of current ARTs, and barriers to medicine for viral infections

Technology Overview

- **The Technology**: Methods of preventing viral infection, including HIV or CMV, using an aryl hydrocarbon receptor (AhR) agonist or *Lachnospriaceae* family bacteria
- **The Discovery**: *Lachnospriaceae* family members *Clostridium immunis* (*C. immunis*) and *Ruminococcus gnavus* (*R. gnavus*) metabolize tryptophan into 3-indolelactic acid (3-ILA) via Aromatic Amino Acid Aminotransferase (ArAT)
- 3-ILA and FICZ (an alternative agonist) can prevent HIV infection by binding to aryl hydrocarbon receptor (AhR)
- **PoC Data**: Administration of *C. immunis* as a live biotherapeutic suppresses active HIV replication by up to 80-90% *in vitro* in an ArAT dependent manner
- Administration of FICZ suppresses active HIV replication by up to 50% *in vitro*

Inventors:
- Ria Goswami
- Neeraj Surana
- Danting Jiang
- Chin Yee Tan

Patents:
- Provisional Filed

Publications:
- N/A

Biz Dev Contact:
- Jamie Brisbois
  - (646) 962-7049
  - jamie.brisbois@cornell.edu

Cornell Reference:
- D-10621

**ART**: Antiretroviral therapy

**AhR**: Aryl hydrocarbon receptor

**ArAT**: Aromatic Amino Acid Aminotransferase
Microbiome-Derived Therapies for Treatment and Prevention of Viral Infections

Technology Applications

- Use of small molecule AhR agonists or *Lachnospriaceae* live biotherapeutics to prevent HIV infection in infants who breast-feed from HIV-positive mothers
- Prevention or treatment of other viral infections including HIV, CMV, and potentially SARS-CoV-2, influenza, Hepatitis C, and Zika

Technology Advantages

- AhR agonists or *Lachnospriaceae* bacteria are broad-spectrum and can be used for co-infections
- Prolonged colonization of *Lachnospriaceae* in patients can prevent the need for re-dosing
- AhR agonists or *Lachnospriaceae* can be used as a monotherapy, rather than in combination like ARTs
- May overcome the toxicity of current ART regimens

Supporting Data / Figures

**Figure 1:** Schematic of HIV inhibition by *C. immunis*. *C. immunis* prevents HIV infection by expressing ArAT, which produces 3-ILA, which activates Ahr.

- **Tryptophan**
  - **C. immunis** → ArAT → 3-ILA → Ahr → FICZ → HIV

<table>
<thead>
<tr>
<th>Inventors:</th>
<th>Ria Goswami Neeraj Surana Danting Jiang Chin Yee Tan</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patents:</td>
<td>Provisional Filed</td>
</tr>
<tr>
<td>Publications:</td>
<td>N/A</td>
</tr>
<tr>
<td>Biz Dev Contact:</td>
<td>Jamie Brisbois (646) 962-7049 <a href="mailto:jamie.brisbois@cornell.edu">jamie.brisbois@cornell.edu</a></td>
</tr>
<tr>
<td>Cornell Reference:</td>
<td>D-10621</td>
</tr>
</tbody>
</table>

**ART:** Antiretroviral therapy  
**AhR:** Aryl hydrocarbon receptor  
**ArAT:** Aromatic Amino Acid Aminotransferase
Supporting Data / Figures

**Inventors:**
Ria Goswami
Neeraj Surana
Danting Jiang
Chin Yee Tan

**Patents:**
Provisional Filed

**Publications:**
N/A

**Biz Dev Contact:**
Jamie Brisbois
(646) 962-7049
jamie.brisbois@cornell.edu

**Cornell Reference:**
D-10621

---

**Figure 1:**

- **A:**
  - *C. immunis*
  - Percent HIV inhibition (normalized to B. fragilis)
  - WT vs. ΔArAT

- **B:**
  - % HIV inhibition (normalized to DMSO)
  - DMSO vs. 3-ILA

- **C:**
  - % HIV inhibition (normalized to DMSO)
  - DMSO vs. FICZ

---

**Figure 1:** a) *C. immunis* prevents HIV infection in an ArAT-dependent manner. b) 3-ILA alone can prevent HIV infection. c) Aryl hydrocarbon receptor (3-ILA target) agonist, FICZ can prevent HIV infection.

---

**ART:** Antiretroviral therapy

**AhR:** Aryl hydrocarbon receptor

**ArAT:** Aromatic Amino Acid Aminotransferase